



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/581,402	06/12/2000	TETSUNORI FUJISAWA	2000_0562A	7196
7590 07/07/2004				
WENDEROTH LIND & PONACK 2033 K STREET NW SUITE 800 WASHINGTON, DC 20006		EXAMINER FREDMAN, JEFFREY NORMAN		
		ART UNIT PAPER NUMBER 1637		

DATE MAILED: 07/07/2004

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER

ART UNIT	PAPER
----------	-------

20040702

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The reply filed on June 8, 2004 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s): There is no election of a Group for examination. Applicant is required to elect a single Group for examination. Applicant's argument that an enablement rejection is an invitation to amend is not found persuasive. Further, Applicant's argument that the compounds have a similar core structure is simply not correct. As noted in the restriction, there is no common core structure between a first compound that comprises an acetimidoyl-L-lysine group and a second compound comprises an aminomethyl-L-phenylalanine compound. These share no common structural features other than the additional groups linked to the substructures. This is even more clearly seen by comparing other group members, some of which further differentiate the structure by having methylsuccinyl or 3-tm-carboxyphenyllpropylsuccinyl groups linked to the base structure. Thus, each inhibitor is distinct, would require a distinct search and lacks any common core structure. Since the above-mentioned reply appears to be *bona fide*, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Jeffrey Fredman
Primary Examiner
Art Unit: 1637
7/1/04